Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Usability of CT-P47 Auto-injector in Rheumatoid Arthritis
NCT05725434Phase 3Unknown
- Sponsor
- Celltrion
- Start
- Feb 2023
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, open-label, single-arm trial of HS628 in rheumatoid arthritis (RA), sponsored by Celltrion. Primary endpoint: Usability of AI as assessed by patients rating using POST-Self-Injection Assessment Questionnaire (SIAQ) at 2 weeks. Status: unknown.
02
Drugs
HS628
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05725434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05725434.